TScan Therapeutics slides in market debut

Tscan Therapeutics

16/07/2021 17:08

** Shares of biopharma co TScan Therapeutics  TCRX.O  fall
20% in Nasdaq debut
    ** Co's shares opened at $12, compared to IPO price of
$15/shr
    ** TCRX sold roughly 6.67 mln shares in its IPO on Thursday,
raising around $100 mln
    ** Co is focused on the development of T-cell based
therapies for the treatment of cancer 
    ** Morgan Stanley, Jefferies, Cowen and Barclays were the
lead underwriters for the offering

 (Reporting by Sohini Podder in Bengaluru)
 ((sohini.podder@thomsonreuters.com))